Citations

Clear

11 citation(s) found for "Fleming, James N".

Performance of a Novel Negative Pressure Wound Therapy Filler in Wound Contraction
Mowers, Colton C., Hilsman, Joe H., Shuler, Michael S. , Fleming, James Coleman, Sarraj, Mohamed , Freedman, Brett A. , Dhodapkar, Meera M, Mowers, Colton C. , Dhodapkar, Meera M.

Mayo Clinic

Wounds: a compendium of clinical research and practice | August 6, 2026 | Volume: 38 | Issue: 8 | Pages: No page available

10.25270/wnds/26050 | PMID 42641019 Get It

Background. Negative pressure wound therapy promotes wound healing through fluid removal, edema reduction, and mechanical contraction. A novel thermoplastic elastomer (TPE) dressing has been developed to improve exudate evacuation and reduce tissue ingrowth, but its effect on wound contraction compared with reticulated open cell foam (ROCF) remains unclear. Objective. To compare the degree of wound contraction with the TPE dressing, ROCF, or no filler at different wound depths and negative pressure settings in a porcine explant model. Materials and Methods. The effect of the materials or lack thereof on wound contraction was investigated at 2 wound depths (shallow, deep) and 3 negative pressure settings (−50 mm Hg, −80 mm Hg, and −125 mm Hg). Wound width was measured at 3 standardized locations before and during therapy. Univariable and multivariable linear regression analyses were performed to identify factors associated with contraction. Results. A total of 810 measurements were obtained. Both the TPE dressing and ROCF demonstrated statistically significantly greater contraction than no filler. In deep wounds, greater contraction was noted with the TPE dressing compared with ROCF. Higher negative pressure and increased wound depth were independently associated with greater contraction. Absolute differences in contraction between dressings were small (<3 mm across all conditions). Conclusion. The TPE dressing provides equivalent or greater wound contraction compared with ROCF, particularly in deep wounds, without impairing macrodeformation. Given the small magnitude of differences, the clinical relevance of this finding likely depends on additional factors, which should be evaluated in future in vivo studies.
Association of Noninvasive Rejection Biomarkers with 10-year Kidney Allograft Survival
Taber, David, Heilman, Raymond L. , Poggio, Emilio, Kurian, Sunil Thuruthummal, Zhao, Lihui, Gebregziabher, Mulugeta , Kleiboeker, Steve, Friedewald, John J, Kurian, Sunil M. , Friedewald, John J. , Fleming, James N , Poggio, Emilio , Kurian, Sunil , Zhao, Lihui , Kleiboeker, Steve , Friedewald, John J , Taber, David, Poggio, Emilio D. , Marsh, Christopher L.

Mayo Clinic

Kidney360 | March 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.34067/kid.0000001167 | PMID 41774503 Get It

Background The primary objective of this analysis was to assess the association between non-invasive biomarker results within the first 2-years post-kidney transplant and 10-year All Cause Graft Loss (ACGL). Methods CTOT-08 was linked with the Scientific Registry of Transplant Recipients (SRTR) to assess 10-year ACGL. Cox Regression was used to determine the association between gene expression profile (GEP) and donor-derived cell-free DNA (dd-cfDNA) results and ACGL. A Cox Regression with time-varying covariates was used to test associations with ACGL with simultaneous and repeated biomarker results. Results The final landmarked Cox model included clinical acute rejection (aHR 2.58 (1,30,5.13) for 1 rejection, aHR 3.41 (1.07,10.85) for 2 rejections), diabetes (aHR 1.71 (0.99,2.96)), recipient age (aHR 1.02 (1.00,1.04)), the highest quartile of positive GEP (aHR 2.44 (1.45,4.10)) and the highest quartile of positive dd-cfDNA (aHR 2.91 (1.77,4.78)). In the time-varying model, having both biomarkers positive at the same time carried the greatest association with ACGL (aHR 4.29 (2.10,8.76)). Conclusions In this multicenter, prospective analysis of GEP and dd-cfDNA on patient and graft outcomes, an independent association with long-term ACGL was demonstrated. Further, a time-varying analysis demonstrated that two biomarkers with independent methodologies tested at the same time can provide more information than either one alone.
Clinical Value of Peripheral Blood Gene Expression Profile and Donor-Derived Cellfree DNA for Identifying Persistent Rejection
Heilman, Raymond L. , Park, S.H., Rebello, Christabel , Kleiboeker, Steve, Holman, John , Friedewald, John J. , Fleming, James N , Holman, John , Friedewald, John J , Kleiboeker, Steve

Mayo Clinic

Kidney360 | August 14, 2024 | Volume: 5 | Issue: 10 | Pages: 1534-1542

10.34067/kid.0000000000000549 | PMID 39480911 Get It

Key Points Peripheral blood biomarkers may have value in monitoring kidney transplant recipients after treatment of acute rejection. The donor-derived cellfree DNA may be more sensitive to identifying antibody-mediated rejection and gene expression profile may be more sensitive to identifying acute cellular rejection. Background Persistent rejection is an increasingly recognized barrier to long-term kidney allograft survival. A noninvasive method to help identify patients with persistent rejection in need of biopsy would be valuable. Methods This was a post hoc analysis of a multicenter observational study. Patients who had a biopsy-proven acute rejection, had another biopsy within 9 months (270 days), and had a biopsy-paired biomarker sample were included. Results A total of 64 index rejections in 58 patients with repeat biopsies were identified with a median time to repeat biopsy of 100 days. Persistent rejection was present in 61%; 69% of follow-up biopsies were performed in clinically stable patients. Peripheral blood gene expression profile (GEP) demonstrated a sensitivity of 59%, specificity of 76%, positive predictive value (PPV) of 79%, and negative predictive value of 54%. Donor-derived cellfree DNA (dd-cfDNA) demonstrated a sensitivity of 62%, specificity of 86%, PPV of 88%, and negative predictive value of 56%. For repeat biopsies within 90 days of rejection in clinically stable patients (63% of repeat biopsies), both GEP and dd-cfDNA had specificities and PPVs of 100%. GEP was more likely to be positive in T-cell–mediated rejection while dd-cfDNA was more likely to be positive in antibody-mediated rejection. Conclusions Both GEP and dd-cfDNA may have utility in identifying clinically stable patients with persistent rejection in need of biopsy; however, they identify different types of rejections. Clinical Trial registration number: NCT01531257.
Multidisciplinary Management of Isocitrate Dehydrogenase–Mutated Gliomas in a Contemporary Molecularly Defined Era
Kotecha, Rupesh , Schiff, David , Chakravarti, Arnab , Fleming, Jessica L. , Brown, Paul D. , Puduvalli, Vinay K. , Vogelbaum, Michael A. , Gondi, Vinai , Gallus, Marco , Okada, Hideho , Chakravarti, Arnab , Schiff, David , Mehta, Minesh P , Puduvalli, Vinay K , Chakravarti, Arnab , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 21 | Pages: 2588-2598

10.1200/jco.23.02195 | PMID 38833641 Get It

Mutations in isocitrate dehydrogenase (IDH) genes, an early step in the ontogeny of lower-grade gliomas, induce global epigenetic changes characterized by a hypermethylation phenotype and are critical to tumor classification, treatment decision making, and estimation of patient prognosis. The introduction of IDH inhibitors to block the oncogenic neomorphic function of the mutated protein has resulted in new therapeutic options for these patients. To appreciate the implications of these recent IDH inhibitor results, it is important to juxtapose historical outcomes with chemoradiotherapy. Herein, we rationally evaluate recent IDH inhibitor data within historical precedents to guide contemporary decisions regarding the role of observation, maximal safe resection, adjuvant therapies, and the import of patient and tumor variables. The biological underpinnings of the IDH pathway and the mechanisms, impact, and limitations of IDH inhibitors, the actual magnitude of tumor regression and patient benefit, and emergence of resistance pathways are presented to guide future trial development. Management in the current, molecularly defined era will require careful patient selection and risk factor assessment, followed by an open dialog about the results of studies such as INDIGO, as well as mature data from legacy trials, and a discussion about risk-versus-benefit for the choice of treatment, with multidisciplinary decision making as an absolute prerequisite.
Multiple abnormal peripheral blood gene expression assay results are correlated with subsequent graft loss after kidney transplantation
Heilman, Raymond L. , Mai, Martin, Smith, Byron H. , Park, Walter D. , Holman, John , Stegall, Mark D. , Smith, Byron , Park, Walter , Holman, John , Stegall, Mark D , Fleming, James N

Mayo Clinic

Clinical Transplantation | April 7, 2023 | Volume: 37 | Issue: 8 | Pages: No page available

10.1111/ctr.14987 | PMID 37026820 Get It

AbstractBackgroundThe aim of this study was to correlate peripheral blood gene expression profile (GEP) results during the first post‐transplant year with outcomes after kidney transplantation.MethodsWe conducted a prospective, multicenter observational study of obtaining peripheral blood at five timepoints during the first post‐transplant year to perform a GEP assay. The cohort was stratified based on the pattern of the peripheral blood GEP results: Tx‐all GEP results normal, 1 Not‐TX had one GEP result abnormal and >1 Not‐TX two or more abnormal GEP results. We correlated the GEP results with outcomes after transplantation.ResultsWe enrolled 240 kidney transplant recipients. The cohort was stratified into the three groups: TX n = 117 (47%), 1 Not‐TX n = 59 (25%) and >1 Not‐TX n = 64 (27%). Compared to the TX group, the >1 Not‐TX group had lower eGFR (p < .001) and more chronic changes on 1‐year surveillance biopsy (p = .007). Death censored graft survival showed inferior graft survival in the >1 Not‐TX group (p < .001) but not in the 1 Not‐TX group. All graft losses in the >1 Not‐TX group occurred after 1‐year post‐transplant.ConclusionsWe conclude that a pattern of persistently Not‐TX GEP assay correlates with inferior graft survival.
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma
Fleming, Jessica L. , Pugh, Stephanie L. , Fisher, Barbara J., Lesser, Glenn J. , Macdonald, David R., Bell, Erica H. , McElroy, Joseph , Becker, Aline Paixão , Timmers, Cynthia , Aldape, Kenneth , Rogers, Leland , Doyle, Thomas J. , Werner‐Wasik, Maria, Bahary, Jean-Paul , Tsai, Ya-Yu , D’Souza, David , Sneed, Penny K. , Kwok, Young , Won, Minhee , Chakravarti, Arnab , Chakravarti, Arnab , Chakravarti, Arnab , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

JCO Precision Oncology | September 1, 2021 | Volume: No volume available | Issue: 5 | Pages: 1397-1407

10.1200/po.21.00112 | PMID 34589661 Get It

PURPOSE This study sought to determine the prognostic significance of the WHO-defined glioma molecular subgroups along with additional alterations, including MGMT promoter methylation and mutations in ATRX, CIC, FUBP1, TERT, and TP53, in NRG/RTOG 0424 using long-term follow-up data. METHODS Mutations were determined using an Ion Torrent sequencing panel. 1p/19q co-deletion and MGMT promoter methylation were determined by Affymetrix OncoScan and Illumina 450K arrays. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method and tested using the log-rank test. Hazard ratios were calculated using the Cox proportional hazard model. Multivariable analyses (MVAs) included patient pretreatment characteristics. RESULTS We obtained complete molecular data to categorize 80/129 eligible patients within the WHO subgroups. Of these, 26 (32.5%) were IDHmutant/co-deleted, 28 (35%) were IDHmutant/non-co-deleted, and 26 (32.5%) were IDHwild-type. Upon single-marker MVA, both IDHmutant subgroups were associated with significantly better OS and PFS ( P values < .001), compared with the IDHwild-type subgroup. MGMT promoter methylation was obtained on 76 patients, where 58 (76%) were methylated and 18 (24%) were unmethylated. Single-marker MVAs demonstrated that MGMT promoter methylation was statistically significant for OS ( P value < .001) and PFS ( P value = .003). In a multimarker MVA, one WHO subgroup comparison ( IDHmutant/co-deleted v IDHwild-type) was significant for OS ( P value = .045), whereas MGMT methylation did not retain significance. CONCLUSION This study reports the long-term prognostic effect of the WHO molecular subgroups, MGMT promoter methylation, and other mutations in NRG/RTOG 0424. These results demonstrate that the WHO molecular classification and MGMT both serve as strong prognostic indicators, but that MGMT does not appear to add statistically significant prognostic value to the WHO subgrouping, above and beyond IDH and 1p/19q status.
Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma
Bell, Erica H. , Shaw, Edward G. , Buckner, Jan C. , Barger, Geoffrey, Bullard, Dennis E., Brown, Paul D. , Stelzer, K. , McElroy, Joseph P., Fleming, Jessica L. , Timmers, Cynthia , Salavaggione, Andrea L., Aldape, Kenneth , Brachman, David, Gertler, Stanley Z., Murtha, Albert , Schultz, Christopher J. , Hunter, G.K., Crocker, Ian , Won, Minhee , Chakravarti, Arnab , Chakravarti, Arnab , Chakravarti, Arnab , Zhang, Jianwen , Mehta, Minesh P. , Gilbert, Mark R. , Becker, Aline Paixão , Liu, Ziyan , Johnson, David, Laack, Nadia N.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2020 | Volume: 38 | Issue: 29 | Pages: 3407-3417

10.1200/jco.19.02983 | PMID 32706640 Get It

PURPOSENRG Oncology/RTOG 9802 (ClinicalTrials.gov Identifier: NCT00003375 ) is a practice-changing study for patients with WHO low-grade glioma (LGG, grade II), as it was the first to demonstrate a survival benefit of adjuvant chemoradiotherapy over radiotherapy. This post hoc study sought to determine the prognostic and predictive impact of the WHO-defined molecular subgroups and corresponding molecular alterations within NRG Oncology/RTOG 9802.METHODSIDH1/2 mutations were determined by immunohistochemistry and/or deep sequencing. A custom Ion AmpliSeq panel was used for mutation analysis. 1p/19q codeletion and MGMT promoter methylation were determined by copy-number arrays and/or Illumina 450K array, respectively. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Hazard ratios (HRs) were calculated using the Cox proportional hazard model and tested using the log-rank test. Multivariable analyses (MVAs) were performed incorporating treatment and common prognostic factors as covariates.RESULTSOf the eligible patients successfully profiled for the WHO-defined molecular groups (n = 106/251), 26 (24%) were IDH-wild type, 43 (41%) were IDH-mutant/non-codeleted, and 37(35%) were IDH-mutant/codeleted. MVAs demonstrated that WHO subgroup was a significant predictor of PFS after adjustment for clinical variables and treatment. Notably, treatment with postradiation chemotherapy (PCV; procarbazine, lomustine (CCNU), and vincristine) was associated with longer PFS (HR, 0.32; P = .003; HR, 0.13; P < .001) and OS (HR, 0.38; P = .013; HR, 0.21; P = .029) in the IDH-mutant/non-codeleted and IDH-mutant/codeleted subgroups, respectively. In contrast, no significant difference in either PFS or OS was observed with the addition of PCV in the IDH-wild-type subgroup.CONCLUSIONThis study is the first to report the predictive value of the WHO-defined diagnostic classification in a set of uniformly treated patients with LGG in a clinical trial. Importantly, this post hoc analysis supports the notion that patients with IDH-mutant high-risk LGG regardless of codeletion status receive benefit from the addition of PCV.
Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424.
Pugh, Stephanie L. , Fisher, Barbara J., Lesser, Glenn J. , Macdonald, David R., McElroy, Joseph P., Rogers, Leland , Doyle, Thomas J. , Werner‐Wasik, Maria, Bahary, Jean-Paul , Yu, Michael , D’Souza, David , Sneed, Patricia Penny, Kwok, Young , Howard, Steven , Chakravarti, Arnab , Bell, Erica H. , Fleming, Jessica L. , Becker, Aline Paixão , Laack, Nadia N. , Mehta, Minesh P.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 2518-2518

10.1200/jco.2020.38.15_suppl.2518 Get It

2518 Background: This study sought to evaluate the prognostic significance of the three WHO-defined molecular glioma subgroups ( IDHwt, IDHmt/non-codel, and IDHmt/codel) in NRG Oncology/RTOG 0424, a phase II trial of high-risk low-grade gliomas treated with radiation (RT) and concurrent and adjuvant temozolomide (TMZ) after biopsy/surgical resection. Notably, this is the first clinical study to evaluate the prognostic value of the WHO subgroups in RT + TMZ-treated high-risk grade II (G2) gliomas using prospectively-collected long-term survival data. Methods: IDH1/2 mutation status was determined by next-generation sequencing. 1p/19q co-deletion status was determined by Oncoscan and/or 450K methylation data. Overall survival (OS) and progression-free survival (PFS) by marker status were determined by the Cox proportional hazard model and tested using the log-rank test in a post-hoc analysis. Patient pre-treatment characteristics were included as covariates in multivariate analyses. Results: Of all the eligible patients (N=129), 80 (62%) had sufficient quality DNA for both IDH and 1p/19q analyses. Of these 80, 54 (67.5%) were IDHmt, and 26 (32.5%) were IDHwt. Of the 54 IDHmt patients, 26 (32.5% of total, 48% of IDHmt) were IDHmt/codel, and 28 (35% of total, 52% of IDHmt) were IDHmt/non-codel. Both IDHmt subgroups were significantly correlated with longer PFS ( IDHmt/co-del = 8.1yrs (5.2-not reached (NR)); IDHmt/non-codel = 7.5yrs (3.9-11.8); IDHwt = 1.0yr (0.6-1.7), p<0.001) and OS ( IDHmt/co-del = 9.4yrs (8.2-NR); IDHmt/non-codel = 8.8yrs (5.9-NR); IDHwt = 2.3yrs (1.4-3.4), p<0.001) relative to the IDHwt subgroup. Upon univariate and multivariate analyses, both molecular IDHmt subgroup comparisons relative to IDHwt remained significant (p<0.001) even after incorporation of known clinical variables. Conclusions: These analyses suggest that G2 glioma patients harboring IDH1/2 mutations, regardless of co-deletion status, demonstrated longer survival with RT + TMZ relative to IDHwt tumors, although sample size is limited and analyses were post-hoc. These results also support the notion that outcomes for IDHwt high-risk G2 gliomas remain dismal (median = 2.3yrs, similar to G3 anaplastic astrocytoma); these patients should be separated from IDHmt patients in future G2 glioma trials, and warrant novel treatment strategies. Funding: U10CA180868, U10CA180822, U24CA196067, CURE, PA Dept. of Health, and Merck. Also, R01CA108633, R01CA169368, RC2CA148190, U10CA180850, BTFC, OSUCCC (all to AC). Clinical trial information: NCT00114140 .
A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia
Sampson, Maureen , Ling, Clarence, Sun, Qian , Harb, Roa , Ashmaig, Mohmed, Warnick, Russell, Sethi, Amar A, Fleming, James K. , Otvos, James D. , Meeusen, Jeff W., Delaney, Sarah , Jaffe, Allan S. , Shamburek, Robert D., Amar, Marcelo , Remaley, Alan T. , Delaney, Sarah R, Meeusen, Jeffrey W. , Jaffe, Allan S.

Mayo Clinic

JAMA Cardiology | February 26, 2020 | Volume: 5 | Issue: 5 | Pages: 540

10.1001/jamacardio.2020.0013 | PMID 32101259 Get It

Updated predictive analysis of the WHO-defined molecular subgroups of low-grade gliomas within the high-risk treatment arms of NRG Oncology/RTOG 9802.
Won, Minhee , McElroy, Joseph P., Shaw, Edward G. , Brachman, David, Gertler, Stanley Z., Murtha, Albert , Schultz, Christopher J. , Johnson, David , Hunter, G.K., Crocker, Ian , Chakravarti, Arnab , Bell, Erica H. , Fleming, Jessica L. , Becker, Aline Paixão , Mehta, Minesh P. , Laack, Nadia N.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 2002-2002

10.1200/jco.2019.37.15_suppl.2002 Get It

2002 Background: This study sought to update the predictive significance of the three WHO-defined molecular glioma subgroups ( IDHwt, IDHmt/noncodel, and IDHmt/codel) in the subset of specimens available for analysis in NRG Oncology/RTOG 9802, a phase III trial of high-risk low-grade gliomas (LGGs) treated with radiation (RT) with and without PCV after biopsy/surgical resection. Notably, this is the first phase III study to evaluate the predictive value of the WHO subgroups in LGGs using prospectively-collected, well-annotated long-term overall survival data, in a post-hoc analysis. Methods: IDH1/2 mutation status was determined by immunohistochemistry and/or next-generation sequencing. 1p/19q status was determined by Oncoscan and/or 450K methylation data. Treatment effects on overall survival (OS) and progression-free survival (PFS) by marker status were determined by the Cox proportional hazard model and tested using the log-rank test in a secondary and exploratory analysis. Results: Of all the randomized eligible high-risk G2 patients (N = 251) in NRG Oncology/RTOG 9802, 106(42%) patients had tissue available with sufficient quality DNA for profiling. Of these, 80(75%) were IDHmut; 43(41%) were IDHmut/non-co-deleted, 37(35%) were IDHmut/co-deleted, and 26(24%) were IDHwt. Upon univariate analyses, no significant difference in either PFS or OS was observed with the addition of PCV in the IDHwt subgroup. Both the IDHmut/non-co-deleted and IDHmut/co-deleted subgroups were significantly correlated with longer PFS (HR = 0.32; p = 0.003; HR = 0.13; p < 0.001) and OS (HR = 0.38; p = 0.013; HR = 0.21; p = 0.029) in the RT plus PCV arm, respectively. Conclusions: Our analyses suggest that both IDHmut/non-co-deleted and IDHmut/co-deleted subgroups received benefit from treatment with PCV although sample size is limited and analyses are post-hoc. Our results also support the notion that IDHwt high-risk LGG patients do not benefit from the addition of PCV to RT. Funding: U10CA180868, U10CA180822, and U24CA196067. Also, R01CA108633, R01CA169368, RC2CA148190, U10CA180850-01, BTFC, OSU-CCC (all to AC). Clinical trial information: NCT00003375.